About

Why Sarepta? Why Now? The promise of genetic medicine has arrived, and Sarepta is at the forefront. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. In 2023, we launched our fourth therapy and the first ever gene therapy to treat Duchenne. We’re looking for people who see unlimited potential in themselves and who are motivated by an unwavering commitment to patients. What Sarepta Offers At Sarepta, we care deeply about all the people in our community and believe in the importance of supporting them in all aspects of their lives. We aspire to maintain a culture that acknowledges people bring their whole selves to work, and we will strive to help everyone in our community integrate their work and personal lives while maintaining productivity. We are committed to offering a range of benefits and work-life resources designed to support people in the following areas: Physical and Emotional Wellness Financial Wellness Support for Caregivers For a full list of our comprehensive benefits, see our website: https://www.sarepta.com/join-us The Importance of the Role The Scientist II, RNA Process Development will contribute to Sarepta’s small‑molecule and oligonucleotide‑related chemistry efforts, supporting development and characterization of intermediates, impurities, and reference standards that enable RNA Drug Substance manufacturing (PMO, PPMO, PMOx, and siRNA). The role will focus on synthetic route design, impurity identification and synthesis, bioconjugation, and bench‑ to pilot‑scale execution. The ideal candidate brings strong problem‑solving skills, hands‑on synthetic chemistry expertise, and the ability to work cross‑functionally in a fast‑paced development environment. This role will directly influence synthetic strategy and contribute to the advancement of Sarepta’s RNA manufacturing platforms. The Opportunity to Make a Difference Design and execute synthetic routes for novel small molecules, intermediates, degradation products, and impurities related to RNA drug substance manufacturing. Develop scalable, robust synthetic procedures; evaluate reaction scope, optimization, and critical process parameters. Identify, elucidate, and synthesize process‑related impurities and degradants using spectroscopic data (NMR, LC‑MS, HRMS, IR). Collect, review, and present process data in group settings and apply statistical methodology to evaluate and optimize process operations. Support scale‑up efforts from milligram to multi‑gram quantities; contribute to tech transfer to internal pilot‑scale labs or external CRO/CMO partners. Evaluate reaction safety, solvent selection, impurity formation mechanisms, and scalability risks. Engage in troubleshooting sessions for processes and products manufactured in-house and at CMOs. Perform technical review of executed Batch Production Records from CMOs during Technology Transfer. Serve as a subject matter expert in cross-functional teams, influencing decisions on CMC strategy, regulatory filings, and risk mitigation. Consistently demonstrate an ability to manage a diverse workload to lead and complete assignments according to project schedules and timelines. Author and review regulatory and technical documents. Other duties as assigned. More about You Advanced degree in Organic Chemistry or related field with 3 – 5 years of experience. Proven track record of leading complex process development projects and influencing technical strategy. Expertise in organic synthesis, flash chromatography, solid-phase synthesis, bioconjugation. Knowledge with oligonucleotide‑related building blocks or phosphoramidite chemistry (preferred but not required). Familiarity with reaction scale‑up fundamentals and lab‑to‑pilot transfer considerations. Understanding of QbD principles, DoE methodology, and statistical modeling tools (JMP, Matlab) are a plus. Strong knowledge of standard oligonucleotide and organic analytical techniques (HPLC, LC-MS, NMR, TLC, GC-MS, IR, etc.). Demonstrated ability to operate independently, exercise judgment in ambiguous situations, and make strategic decisions. Exceptional communication skills for influencing leadership and external stakeholders. Commitment to Sarepta’s cultural values Exercises judgment within broadly defined practices and policies in selecting methods, techniques and evaluation criteria for obtaining results. Demonstrates effective written and verbal communication skills. Able to handle multi-task workload and perform duties in a fast-paced environment. What Now? We’re always looking for solution-oriented, critical thinkers. So, if you’re comfortable with ambiguity and candor, relish challenging yourself, and place kindness and integrity at the forefront of how you approach your peers and work, then we encourage you to apply. #LI-Onsite Blank This position requires work on site at one of Sarepta’s facilities in the United States. The targeted salary range for this position is $112,000 - $140,000 per year. Sarepta is making a good faith effort to be transparent and accurate around our hiring ranges. The salary offer is commensurate with Sarepta’s compensation philosophy and considers factors including, but not limited to, education, training, experience, external market conditions, criticality of role, and internal equity. Candidates must be authorized to work in the U.S. Sarepta Therapeutics offers a competitive compensation and benefit package. Sarepta Therapeutics is an Equal Opportunity/Affirmative Action employer and participates in e-Verify. Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. Our deep pipeline is driven by our multi-platform technologies in siRNA, RNA and gene therapy. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.